Posted on

hidradenitis suppurativa cbd oil

Astonishing results! Suffering from Narcissistic Abuse Trauma Syndrome and multiple body problems due to long term abuse. In the first 8 hours of use, my mind started to clear, the fog lifted and thinking processes started to return to proper function.

The health advisor at my health food store SAID that CBD Oils, vaped, give the best infusion of terpenes, immediately going to the brain as inhalation occurs. She also had stated that neural pathways are REGENERATED and are often returned to full function.

I had a friend who purchased hemp salve from Straight Hemp Company. She asked if I would like to try some of the hemp salve on the open wound under my right axillary area. Reluctantly I said yes. I say reluctantly because I have tried so many creams, antibiotic ointments etc, and none of them have helped the open wound. So this friend applied some of the Straight Hemp salve into a small container for me to bring home with me. I did not want to take the chance of contaminating her salve. After one application of Straight Hemp salve, the pain immediately eased. I noticed a significant change in the pain. After several days of applying the hemp salve, the wound began to close. The amount of drainage also began to slow down. I got the wound closed and stopped applying the salve, as an experiment to see how long the axillary area would stay healthy.

A testimonial from Karen S. using Straight Hemp CBD Vape Oil

My husband has arthritis in his ankles that is often aggravated by the machinery he works on – salve before bed takes the pain away. In our household we use it for all the bumps and bruises, muscle pains, soreness, etc.

Personally, I have gut issues that would otherwise keep me full of inflammation; this salve helps with joint pain. I also rub it on my belly when my guts are in turmoil. As a Crossfitter, it helps with aches in my sore muscles. As a female, it works wonders for cramping. …knots in my neck. I could go on.

This salve has really made a difference in this disease for me. I know everyone and their body’s are different and individual. I’m not saying this hemp salve is a cure for Hidradenitis Suppurativa. I’m just simply sharing my experience with the hemp salve and how it has helped my particular situation with this chronic disease. If it has helped me so greatly, it my possibly help others with this horrible disease. If I can share my story and experience with this salve, and it reaches just one person who also suffers from Hidradenitis Suppurativa I will be happy. Maybe that one person or more can have a better quality of life. I would like to thank everyone at Straight Hemp Company for all you do. Thank you for making this product and allowing chronic illness survivors lives a little easier!

Not long after ceasing to apply the salve, I developed another lesion under the same arm, just in a different spot. This lesion tunneled under the skin back to that same wound, started draining and reopened the wound. So I have now started reapplying the hemp salve. The open wound is already starting to improve.

Methods: This cross-sectional analysis of adult HS patients (n = 32,625) identified using electronic health records data was pulled from a population-based sample of >50 million patients.

Background: Patients with hidradenitis suppurativa (HS) experience chronic pain and have significant physical, emotional, and psychological disease impact. These patients may be at risk for substance abuse.

Conclusion: Patients with HS have higher odds of SUD and may benefit from periodic screening for substance abuse.

Objective: To evaluate substance use disorder (SUD) among patients with HS in the United States.

Keywords: Explorys; alcohol; cannabis; hidradenitis suppurativa; misuse; opioid; substance use.

The YAKAR form of medical cannabis license application and a confidentiality waiver form will be sent to the YAKAR. The physician will explain to the patients that his/her participation in the trial can be terminated at any time and will explain the medical license conditions: It is absolutely forbidden to:

Forty participants will be recruited over two years. After determine eligibility by examining the study criteria for inclusion and exclusion, the patient will be asked to sign the informed consent form.

The participants will be randomly assigned in a 1:1 ratio to receive Avidekel oil or placebo oil. Patients will receive the oils as drops applied under the tongue 3 times a day.

When the patient license arrives, the patient will be scheduled an appointment for the first visit of the trial at the hospital. Tikun-Olam will be informed and asked to supply the patient product on the visit day. The copy of the patient’s license will be included into the trial source documents.

The duration of study participation for each subject is expected to be 12 weeks (84 days), about 4 weeks from visit 0 until receiving the license and 8 weeks trial,of which, six weeks of dose titration. Over the course of twelve weeks, four visits will be conducted and there will be 3 telephone evaluations. During first visit screening and enrolment will be conducted. The second visit will take place four weeks later where patients will receive the oils and start the trial, followed by a phone call evaluation at day 5-7 after starting the treatment and at week 2±2 days. Than a visit approximately four weeks later, following another phone call evaluation at week 5±2 days from treatment beginning, F Last visit will be conducted at week 8±3 days. In each visit, the relevant variables will be collected (Please refer to Table 3. Schedule of events). At the end of the eight-week experiment, patients from the treatment and control groups will be given the option to use the Avidekel oil for a period of one year. First, all the patients will use the drug in the open label phase for 8 weeks, during this period 3 phone calls and 2 visits in the hospital will be conducted, using PI-NRS and HS-PGA score to evaluate treatment success. Patients who will have at least 1 point reduction on the HS-PGA score will be permitted to continue to the 1 year follow-up. During that period 2 visits, six months and one year, will be conducted and the relevant variables will be collected (see Table 3). All visits will take place at the hospital.